Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
123 Leser
Artikel bewerten:
(0)

Research and Markets - Global Predictive Genetic Testing And Consumer/Wellness Genomics Market 2013-2017 & 2025: Key Players are BGI, Illumina, Pathway Genomics, Genesis, 23andMe, ARUP, Color Genomics & Myriad

DUBLIN, Apr. 28, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Predictive Genetic Testing And Consumer/Wellness Genomics Market By Application And Trend Analysis From 2013 To 2025" report to their offering.

Research and Markets Logo

The global predictive genetic testing & consumer/wellness genomics market is anticipated to reach USD 4.6 billion by 2025

Key drivers attributing to the market expansion include rising awareness pertaining to the use of genomic tests for the prediction of gene susceptibility for probability of disease development. Genetic data in the ecosystem increases when consumers buy direct-to-consumer genomics products or participate in clinical research trials.

Rising encouragement for the use of these products is anticipated to propel industrial growth. Expansion in the range of consumer genetic tests by market entities is anticipated to fuel progress in the market in the coming years. Introduction of novel platforms anticipates the DNA-powered applications thus rising market penetration.

Moreover, the pharmaceutical companies are also engaged in partnerships with genomics companies in order to develop novel therapeutics on the basis of genotypic and phenotypic correlations. For instance, in April 2016 a ten-year deal was signed between Human Longevity Inc. (HLI) and AstraZeneca, in which HLI is supposed to sequence 500,000 genomes of the clinical trial population of AstraZeneca. This data is to be used for the identification of novel drug targets. The deal also provides AstraZeneca with access to the proprietary knowledgebase in order augment biomarker discovery, and facilitate drug development.

Further Key Findings from the Study Suggest:

  • Application of genetic susceptibility tests in gynecology and endocrinology, is of great interest thereby resulting to higher adoption.
  • These tests enable the identification of the susceptibility of genes towards postmenopausal osteoporosis, adenomyosis, and endometriosis.
  • Breast & ovarian cancer based predictive testing accounted for the largest share owing to the rising use of susceptibility testing for BRCA mutations cancer prediction.
  • Government and pertinent organizations are engaged in endeavors aimed at curbing cancer-related healthcare expenditure by encouraging patients to undergo regular diagnostic examinations.
  • CRC screening initiatives undertaken by the governments and implementation of mass CRC screening programs is expected to increase the demand for CRC screening tests.
  • Asia Pacific is anticipated to witness substantial growth in the coming years owing to accelerated uptake of these predictive tests in the developing economies of this region.
  • Key players contributing in this market are BGI, Illumina, Inc, Pathway Genomics, Genesis Genetics, 23andMe, Inc, ARUP Laboratories, Color Genomics Inc., and Myriad Genetics, Inc.
  • These entities are involved in collaborations in order to develop their portfolio with respect to fragmented point-solutions across the genomics value chain.

Key Topics Covered:

1 Research Methodology

2 Executive Summary

3 Predictive Genetic Testing & Consumer/Wellness Genomics Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market Driver Analysis
3.1.1.1 Rise in number of novel partnership models
3.1.1.2 Introduction of fragmented point-solutions across the genomics value chain
3.1.1.3 Exponentially decreasing costs for genetic sequencing
3.1.1.4 Introduction of technological advancements in cloud computing and data integration
3.1.2 Market Restraint Analysis
3.1.2.1 Absence of well-defined regulatory framework and low adoption rate
3.1.2.2 Ethical concerns pertaining to implementation
3.2 Penetration & Growth Prospect Mapping for Applications, 2015
3.3 Predictive genetic testing & consumer/wellness genomics-Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis - Porter's

4 Predictive Genetic Testing & Consumer/Wellness Genomics Market: Test Type Estimates & Trend Analysis
4.1 Predictive Genetic Testing & Consumer/Wellness Genomics Market: Test Types Movement Analysis
4.2 Predictive Testing
4.2.2 Genetic susceptibility test
4.2.3 Predictive diagnostics
4.2.4 Population screening programs
4.3 Consumer Genomics
4.4 Wellness Genetics
4.4.2 Nutria Genetics
4.4.3 Skin & Metabolism Genetics
4.4.4 Others

5 Predictive Genetic Testing & Consumer/Wellness Genomics Market: Application Estimates & Trend Analysis
5.1 Predictive Genetic Testing & Consumer/Wellness Genomics Market: Application Movement Analysis
5.2 Breast & Ovarian Cancer Screening
5.3 Cardiovascular Screening
5.4 Diabetic Screening & Monitoring
5.5 Colon Cancer Screening
5.6 Parkinsonism / Alzheimer's disease
5.7 Urologic Screening/ Prostate Cancer Screening
5.8 Orthopedic & Musculoskeletal Screening
5.9 Other Cancer Screening
5.10 Other Diseases Screening

6 Predictive Genetic Testing & Consumer/Wellness Genomics Market: Regional Estimates & Trend Analysis, by Test Type & Application

7 Competitive Landscape

  • F. Hoffmann-La Roche Ltd
  • 45 Life Sciences (Roche Diagnostics Corporation)
  • Abbott (Abbott Diagnostics)
  • Thermo Fisher Scientific, Inc.
  • Affymetrix, Inc.
  • Applied Biosystems
  • Agilent Technologies
  • BGI
  • Complete Genomics Incorporated
  • Bio-Rad Laboratories, Inc.
  • GnuBIO, Inc.
  • Illumina, Inc.
  • QIAGEN
  • Alere
  • Myriad Genetics, Inc.
  • Siemens Healthineers
  • Pathway Genomics
  • Cooper Surgical, Inc.
  • Genesis Genetics
  • Reprogenetics
  • Ambry Genetics Corporation
  • 123andMe, Inc.
  • Danaher
  • Beckman Coulter, Inc.
  • Cepheid
  • Hologic, Inc. (Gen-Probe Incorporated)
  • ARUP Laboratories
  • GUARDANT HEALTH, INC
  • Advanced Genomic Solutions (AGS) Ltd
  • EasyDNA
  • Color Genomics, Inc.
  • Counsyl, Inc.
  • Gene by Gene
  • Mapmygenome
  • Interleukin Genetics Inc.
  • Laboratory Corporation of America Holdings (LabCorp)
  • Quest Diagnostics Incorporated
  • Sonora Quest Laboratories
  • Xcode
  • Amgen, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/hdjzfv/predictive

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

© 2017 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.